RxDoctor Payments Data

Holly Wilson, NP

Nurse Practitioner · Booneville, MSNPI 1407407273

Payments from drug & device makers

$2,781in general payments, 2019–2025

Across 165 payments — averaging $16.86 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$892
  • Verona Pharma, Inc.$441
  • Regeneron Healthcare Solutions, Inc.$289
  • Sanofi$276
  • AstraZeneca$224
  • Insmed, Inc.$204
  • plus $456 from 8 others

What the payments were for

  • Food & beverage$2,76499%
  • Education$171%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,781 in reported general payments places this provider in the 85th percentile of 1,090 nurse practitioner providers in Mississippi.

See all nurse practitioner providers in Mississippi

Medicare billing

Part B allowed, 2024
$18,583
Medicare patients
196
Services billed
222

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter60$38,948
Theophylline ErTheophylline Anhydrous29$1,412
Cefdinir45$897
Albuterol Sulfate HfaAlbuterol Sulfate29$801
Metoprolol Succinate28$532
Fluticasone Propionate26$271
Omeprazole11$179
Montelukast Sodium18$159
Famotidine18$149
Rosuvastatin Calcium14$147
Nystatin13$127
Methylprednisolone16$112
Hydralazine Hcl11$102
Losartan Potassium16$96
Potassium Chloride11$87

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta$892$38,94860 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,090 nurse practitioner providers in Mississippi.

Other nurse practitioner in Booneville

See the full list for Mississippi

Where these figures come from

Is this you, or does something look wrong? →